MetaCap

Armata Pharmaceuticals (ARMP) vs Molecular Partners (MOLN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Molecular Partners (MOLN) has outperformed Armata Pharmaceuticals (ARMP) over the past year, losing 37.5% versus a loss of 56.9%. Over five years, ARMP leads with a -42.0% price change compared with -77.9% for MOLN. Armata Pharmaceuticals is the larger company by market cap ($112.7 million vs $96.8 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARMP-56.90%MOLN-37.50%
+119%+24%-71%
Nov 21, 20251 yearNov 20, 2026
ARMP-22.70%MOLN-75.84%
+245%+77%-91%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARMP versus MOLN key metrics
MetricARMPMOLN
Share price$3.03$2.53
Market cap$112.69M$96.80M
1-day change+1.68%-5.25%
YTD return-51.75%-42.07%
1-year return-56.90%-37.50%
5-year return-41.95%-77.87%
EPS (TTM)$-4.17$-1.68
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-173.80M—
52-week high$14.98$5.36
52-week low$2.40$2.52
Distance from 52-week high-79.77%-52.89%
Analyst consensusnonestrong_buy
Avg. price target upside+477.56%+295.64%
Average volume182.52K1.63K
Shares outstanding37.19M38.34M
Employees61134
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MOLN has outperformed ARMP by 19.4 percentage points over the past year.

About Armata Pharmaceuticals

ARMP stock →

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees

About Molecular Partners

MOLN stock →

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees

ARMP vs MOLN FAQ

Which is bigger, Armata Pharmaceuticals or Molecular Partners?

Armata Pharmaceuticals (ARMP) is larger, with a market capitalization of $112.69M compared with $96.80M for Molecular Partners (MOLN).

Which stock has performed better over the past year, ARMP or MOLN?

MOLN returned -37.50% over the past 12 months, compared with -56.90% for ARMP (price return, excluding dividends). Past performance does not predict future results.

Are Armata Pharmaceuticals and Molecular Partners in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons